Utilising Non-Viral DNA Delivery to Define a Third Path for In Vivo CAR-T Therapies

• Exploring how single-stranded DNA delivery combines the advantages of non-viral manufacturing with the durability required for lasting therapeutic responses
• Showcasing emerging preclinical evidence supporting durable, relapse-resistant CAR-T therapies generated entirely through non-viral approaches

Speakers:

Edward Rebar

Chief Scientific Officer

CPTx